|
 |
|
|||||||
|
|||||||||
© 2005 by the American Diabetes Association, Inc.
Pathophysiology/Complications |
The Influence of Adiponectin Gene Polymorphism on the Rosiglitazone Response in Patients With Type 2 Diabetes
1 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
2 Department of Internal Medicine, Kwandong University College of Medicine, Gangneung, Korea
3 Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea
Address correspondence and reprint requests to Hyun Chul Lee, Department of Internal Medicine, Yonsei University College of Medicine, 134 Shinchon-Dong Seodaemun-Gu, Seoul, 120-752, Korea. E-mail: endohclee{at}yumc.yonsei.ac.kr
OBJECTIVE —The aim of this study was to examine the effects of rosiglitazone on adiponectin and plasma glucose levels in relation with common adiponectin gene (ACDC) polymorphisms.
RESEARCH DESIGN AND METHODS —A total of 166 patients with type 2 diabetes were treated with rosiglitazone (4 mg/day) for 12 weeks without changing any of their previous medications. In all, single nucleotide polymorphism (SNP)45 and SNP276 of ACDC were examined.
RESULTS —Regarding SNP45, there was a smaller reduction in the fasting plasma glucose (FPG) level and the HbA1c value in the carriers of the GG genotype than in the carriers of the other genotypes (P = 0.031 and 0.013, respectively). There was a smaller increase in the serum adiponectin concentration for the GG genotype than for the other genotypes (P = 0.003). Regarding SNP276, there was less reduction in the FPG level for the GG genotype than for the other genotypes (P = 0.001). In the haplotype analysis, the reductions in the FPG and HbA1c levels were smaller for the GG homozygote haplotype than for the other haplotypes (P = 0.001 and 0.001, respectively). The increase in the plasma adiponectin concentration for the GG homozygote haplotype was smaller than that of the other haplotypes (P = 0.003).
CONCLUSIONS —These data suggest that genetic variations in the adiponectin gene can affect the rosiglitazone treatment response of the circulating adiponectin level and blood glucose control in type 2 diabetic patients.
Abbreviations: FPG, fasting plasma glucose • HOMA-IR, homeostasis model assessment of insulin resistance • PPAR, peroxisome proliferator–activated receptor • PPRE, PPAR responsive element • SNP, single nucleotide polymorphism.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  V. G. Kaklamani, M. Sadim, A. Hsi, K. Offit, C. Oddoux, H. Ostrer, H. Ahsan, B. Pasche, and C. Mantzoros Variants of the Adiponectin and Adiponectin Receptor 1 Genes and Breast Cancer Risk Cancer Res., May 1, 2008; 68(9): 3178 - 3184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Menzaghi, V. Trischitta, and A. Doria Genetic Influences of Adiponectin on Insulin Resistance, Type 2 Diabetes, and Cardiovascular Disease Diabetes, May 1, 2007; 56(5): 1198 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Han, M. J. Quon, J.-a Kim, and K. K. Koh Adiponectin and Cardiovascular Disease: Response to Therapeutic Interventions J. Am. Coll. Cardiol., February 6, 2007; 49(5): 531 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Kang, B. S. Cha, H. J. Kim, H. J. Kim, S. H. Kim, K. Y. Hur, H. J. Lee, W. S. Shim, C. W. Ahn, and H. C. Lee The 11482G>A Polymorphism in the Perilipin Gene Is Associated With Weight Gain With Rosiglitazone Treatment in Type 2 Diabetes. Diabetes Care, June 1, 2006; 29(6): 1320 - 1324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Wolford, K. A. Yeatts, S. K. Dhanjal, M. H. Black, A. H. Xiang, T. A. Buchanan, and R. M. Watanabe Sequence Variation in PPARG May Underlie Differential Response to Troglitazone Diabetes, November 1, 2005; 54(11): 3319 - 3325. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |